AR034216A1 - Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus - Google Patents

Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus

Info

Publication number
AR034216A1
AR034216A1 ARP020100923A ARP020100923A AR034216A1 AR 034216 A1 AR034216 A1 AR 034216A1 AR P020100923 A ARP020100923 A AR P020100923A AR P020100923 A ARP020100923 A AR P020100923A AR 034216 A1 AR034216 A1 AR 034216A1
Authority
AR
Argentina
Prior art keywords
virus
detergent
reovirus
compositions
minutes
Prior art date
Application number
ARP020100923A
Other languages
English (en)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR034216A1 publication Critical patent/AR034216A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un método para producir virus a partir de un cultivo de células, que comprende los pasos de: (a) proveer un cultivo de células que ha sido infectado por el virus; (b) extraer el virus de las células por adición de un detergente al cultivo e incubación por un período de tiempo; y (c) recolectar el virus. Se pueden extraer virus infecciosos del cultivo con un detergente a una temperatura conveniente, tal como 25°C ó 37°C, para obtener títulos virales altos. Se pueden usar detergentes no iónicos y iónicos. Particularmente, el detergente se selecciona del grupo formado por Tritón X-100, Tween 20, NP-40 y deoxicolato de sodio. Se prefiere que el detergente sea Tritón X-100, en particular a una concentración final del 1%. El cultivo celular se incuba con el detergente en un período de tiempo suficiente como para provocar la ruptura de las células. El período de incubación es preferentemente de 60 minutos o menos, más preferentemente de 30 minutos o menos y más preferentemente aún de 10 minutos. En una realización preferida el virus es un virus sin envoltura. El virus sin envoltura es preferentemente un reovirus, particularmente un reovirus mamífero. Los reovirus de mamíferos son preferentemente reovirus humanos, más preferentemente el serotipo 3 de reovirus y con mayor preferencia el reovirus de la cepa Dearing. Se describen composiciones que comprenden el virus recolectado, en particular composiciones adecuadas para la administración clínica. Preferiblemente el virus es reovirus. Las composiciones pueden también comprender un excipiente y/o vehículo aceptable para uso farmacéutico.
ARP020100923A 2001-03-16 2002-03-14 Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus AR034216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27673401P 2001-03-16 2001-03-16

Publications (1)

Publication Number Publication Date
AR034216A1 true AR034216A1 (es) 2004-02-04

Family

ID=29420186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100923A AR034216A1 (es) 2001-03-16 2002-03-14 Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus

Country Status (14)

Country Link
US (2) US6808916B2 (es)
EP (2) EP1370643A1 (es)
JP (2) JP4087712B2 (es)
AR (1) AR034216A1 (es)
BR (1) BR0207527A (es)
CA (1) CA2437962C (es)
DK (1) DK2253701T3 (es)
ES (1) ES2500645T3 (es)
HK (1) HK1150859A1 (es)
IL (2) IL157304A0 (es)
MX (1) MXPA03007535A (es)
NZ (1) NZ527525A (es)
WO (1) WO2002074940A1 (es)
ZA (1) ZA200306228B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1501921T4 (da) 2002-04-30 2012-10-08 Oncolytics Biotech Inc Forbedrede virusrensningsmetoder
EP1634947A4 (en) * 2003-06-10 2007-10-03 Shimadzu Corp EXTRACT FROM A CULTURED MAMMALIAN CELL, PROCESS FOR THEIR PREPARATION AND METHOD FOR CELL-FREE PROTEIN SYNTHESIS USING THE EXTRACT
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP2952583A1 (en) 2007-03-12 2015-12-09 Oncolytics Biotech Inc. Reoviruses having modified sequences
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
EP2211880A4 (en) * 2007-10-22 2012-11-14 Oncolytics Biotech Inc TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES
CN201163385Y (zh) * 2008-01-15 2008-12-10 昆山渝榕电子有限公司 笔记本电脑及其脚垫
JP2011520994A (ja) * 2008-05-27 2011-07-21 オンコリティクス バイオテク,インコーポレーテッド 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
CA2832367A1 (en) 2011-04-29 2012-11-01 Oncolytics Biotech Inc. Methods of purifying viruses using gel permeation chromatography
KR102186997B1 (ko) * 2013-03-15 2020-12-07 안선 바이오파르마, 아이엔씨. 단백질 정제의 신규한 방법
EP3068411B1 (en) 2013-11-15 2020-03-18 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
US10280199B2 (en) 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
WO2016130569A1 (en) * 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
DK3172317T3 (da) * 2014-07-24 2019-07-22 Janssen Vaccines & Prevention Bv Fremgangsmåde til oprensning af poliovirus fra cellekulturer
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
WO2023277173A1 (ja) * 2021-06-30 2023-01-05 旭化成メディカル株式会社 ウイルスの回収方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS6344532A (ja) 1986-08-11 1988-02-25 Biseibutsu Kagaku Kenkyusho:Kk 豚のレオウイルス感染症ワクチン
US5614413A (en) * 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
EP0968284B1 (en) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6214333B1 (en) * 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
EP1370643A1 (en) 2003-12-17
ES2500645T3 (es) 2014-09-30
US6808916B2 (en) 2004-10-26
EP2253701B1 (en) 2014-08-13
EP2253701A1 (en) 2010-11-24
US20050095692A1 (en) 2005-05-05
CA2437962A1 (en) 2002-09-26
WO2002074940A1 (en) 2002-09-26
HK1150859A1 (en) 2012-01-13
JP2007295937A (ja) 2007-11-15
JP4087712B2 (ja) 2008-05-21
IL157304A (en) 2010-04-29
ZA200306228B (en) 2004-08-12
NZ527525A (en) 2005-03-24
BR0207527A (pt) 2004-02-25
US7186542B2 (en) 2007-03-06
JP2004520841A (ja) 2004-07-15
CA2437962C (en) 2005-11-15
DK2253701T3 (da) 2014-10-20
US20020168764A1 (en) 2002-11-14
MXPA03007535A (es) 2003-12-11
IL157304A0 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
AR034216A1 (es) Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus
Weaver et al. Population bottlenecks and founder effects: implications for mosquito-borne arboviral emergence
Maclachlan et al. Bluetongue
Weger-Lucarelli et al. Vector competence of American mosquitoes for three strains of Zika virus
McLean et al. A novel insect-specific flavivirus replicates only in Aedes-derived cells and persists at high prevalence in wild Aedes vigilax populations in Sydney, Australia
AR039783A1 (es) Metodos mejorados de purificacion viral
Guan et al. Molecular epidemiology of H5N1 avian influenza
Aguilar-Setien et al. Salivary excretion of rabies virus by healthy vampire bats
AR033993A1 (es) Metodo para producir reovirus infeccioso y de mamifero, y composicion de reovirus
EA200200604A1 (ru) Производство вакцин
Diagne et al. Vector competence of Aedes aegypti and Aedes vittatus (Diptera: Culicidae) from Senegal and Cape Verde archipelago for West African lineages of chikungunya virus
ES2895148T3 (es) Procesos para la producción y purificación de composiciones que contienen ácidos nucleicos
ES2421543T3 (es) Método para la preparación de virus y proteínas del PRRS, y kits de pruebas de diagnóstico para su detección
Katz et al. The significance of failure to isolate infectious viruses in cases of subacute sclerosing panencephalitis
Del Amo et al. Experimental infection of house sparrows (Passer domesticus) with West Nile virus strains of lineages 1 and 2
Planzer et al. In vivo and in vitro propagation and transmission of Toggenburg orbivirus
AR079710A1 (es) Proceso para el cultivo de celulas adherentes
Ng et al. Topographic changes in SARS coronavirus–infected cells at late stages of infection
Sudeep et al. Preliminary findings on Bagaza virus (Flavivirus: Flaviviridae:) growth kinetics, transmission potential & transovarial transmission in three species of mosquitoes
Jadi et al. Chandipura virus growth kinetics in vertebrate cell lines, insect cell lines & embryonated eggs
Koptopoulos et al. The epizootology of caprine herpesvirus (BHV-6) infections in goat populations in Greece
Skern 100 years poliovirus: from discovery to eradication. A meeting report
Jørgensen Indirect fluorescent antibody techniques for demonstration of trout viruses and corresponding antibody
Webb et al. Argentine and Bolivian hemorrhagic fevers (South American hemorrhagic fevers)
Koski A RHABDOVIRUS ISOLATED FROM BROWN TROUT (SALMO TRUTTA m. LACUSTRIS (L.)) WITH LESIONS IN PARENCHYMATOUSn

Legal Events

Date Code Title Description
FB Suspension of granting procedure